Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP8232 in diabetic macular edema
NCT02302079Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ASP8232 in diabetic macular edema (DME) (3 arms), sponsored by Astellas Pharma. Primary endpoint: Percent change from baseline in excess central subfield thickness at 3 months. Started Jan 2015; status: completed.
02
Drugs
ASP8232
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02302079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02302079.